MLM Biologics awarded $1.5m to develop new medical device for wound infection treatment
MLM Biologics, a privately held medical device company, has been awarded approximately $1.5 million by the US Army Medical Research and Development Command (USAMRDC).
Under the award, MLM Biologics will develop a new medical device to prevent infection in battlefield wounds from “…complex, traumatic, penetrating injuries in a far-forward, austere environment.”
The device will incorporate MLM Biologic’s proprietary collagen processing and stabilization technologies combined with proven anti-inflammatory and anti-microbial components.
Chandra Nataraj — MLM Biologics CEO said: “We’re honored to bring our innovative solutions to the men and women who stand in harm’s way as our focus has always been on wound closure—not just wound management.”
“We expect to make a difference, not only for our military heroes, but eventually for everyone dealing with possible wound infection.
“The potential health benefits are huge.”
It is believed the device will eventually be available for civilian clinical use.
Karl R LaPan — UF Innovate | Accelerate director said: “MLM Biologics, and the development of a treatment to prevent wound infection, is a great example of public-private partnerships translating research into meaningful, life-changing products for America’s service members.”
MLM Biologics has labs at the University of Florida’s business incubator, UF Innovate | Accelerate @ Sid Martin Biotech for product development activities.
The biologic medical devices manufacturer currently distributes an FDA-cleared wound care device bio-ConneKt Wound Matrix out of its Gainesville facility, Florida.
The award, which is part of the Military Prototype Advancement Initiative, was funded by the Department of Defense and issued through the Medical Technology Enterprise Consortium, a partnership of industry and academia to enable research and development activities with USAMRDC and other government agencies.